Resiniferatoxin was not associated with sustained differences in the review outcomes reported but pain during instillation and withdrawal from treatment was significantly more common .
Groups treated with BCG tended to report less pain and fewer general symptoms .
Although adverse events were commonly reported , these were no more common after BCG than after placebo instillation .
The few data about Pentosanpolysulphate tended to favour the actively treated , but with wide confidence intervals ; there was little information about adverse events .
Oxybutinin instillation was associated with increased bladder capacity , reduced frequency , improved quality of life scores and fewer drop-outs .
Alkalinisation of urine pH did not make any clear difference , but with potentially wide confidence intervals .
BCG and oxybutin are reasonably well-tolerated and evidence is most promising for these .
Resiniferatoxin showed no evidence of effect for most outcomes and caused pain , which reduced treatment compliance .
There is little evidence for the other treatments included in this review .
BACKGROUND Painful Bladder Syndrome/Interstitial Cystitis ( PBS/IC ) occurs predominantly in women .
It is a poorly-understood condition with symptoms of bladder pain , urinary frequency , urgency and nocturia .
Treatments for PBS/IC include dietary/lifestyle interventions , oral medication , intravesical instillations and , in some cases , surgery .
Success rates are generally modest and there is little consensus as to the best form of treatment for this condition .
OBJECTIVES To assess the effectiveness of intravesical treatment for PBS/IC .
Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC)
Objective : To determine the safety and tolerability of intravesical resiniferatoxin ( RTX ) in interstitial cystitis ( IC ) patients . Material s and Methods : IC patients were instilled with 50 cc of test solution containing either placebo , 0.05 μM or 0.10 μM RTX in the bladder . Plasma concentration of RTX and its degradant resiniferonol 9- , 13- , 14-orthophenylacetate was measured . Immediate post-treatment blood sampling and cystoscopy were performed . Symptoms were evaluated before treatment , at 4- and at 12-week follow-ups , using VAS indicator for pain , voiding diary , and O’Leary ’s IC symptom/problem indices . Results : Among 22 patients observed ( ten in 0.10 μM RTX , eight in 0.05 μM RTX , and four in placebo groups ) , the most commonly reported adverse event was pain during instillation ( 80.0 % , 87.5 % , and 25.0 % ) . No serious adverse events were reported . Conclusions : Use of intravesical RTX in IC patients is associated with important tolerability issues but safe at 0.10 μM and 0.05
Resiniferatoxin was not associated with sustained differences in the review outcomes reported but pain during instillation and withdrawal from treatment was significantly more common .
Groups treated with BCG tended to report less pain and fewer general symptoms .
Although adverse events were commonly reported , these were no more common after BCG than after placebo instillation .
The few data about Pentosanpolysulphate tended to favour the actively treated , but with wide confidence intervals ; there was little information about adverse events .
Oxybutinin instillation was associated with increased bladder capacity , reduced frequency , improved quality of life scores and fewer drop-outs .
Alkalinisation of urine pH did not make any clear difference , but with potentially wide confidence intervals .
BCG and oxybutin are reasonably well-tolerated and evidence is most promising for these .
Resiniferatoxin showed no evidence of effect for most outcomes and caused pain , which reduced treatment compliance .
There is little evidence for the other treatments included in this review .
BACKGROUND Painful Bladder Syndrome/Interstitial Cystitis ( PBS/IC ) occurs predominantly in women .
It is a poorly-understood condition with symptoms of bladder pain , urinary frequency , urgency and nocturia .
Treatments for PBS/IC include dietary/lifestyle interventions , oral medication , intravesical instillations and , in some cases , surgery .
Success rates are generally modest and there is little consensus as to the best form of treatment for this condition .
OBJECTIVES To assess the effectiveness of intravesical treatment for PBS/IC .